PURE Pure Bioscience

PURE Bioscience, Inc. engages in the discovery, development, and commercialization of proprietary antimicrobial products for pathogen and hygienic control. It offers silver dihydrogen citrate-based disinfecting and sanitizing products. The company was founded by Michael L. Krall on August 24, 1992 and is headquartered in Rancho Cucamonga, CA.
Company profile
Ticker
PURE
Exchange
Website
CEO
Tom Y. Lee
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
INNOVATIVE MEDICAL SERVICES, PURE BIOSCIENCE
SEC CIK
Corporate docs
IRS number
330530289
PURE stock data
()
Investment data
Securities sold
Number of investors
Calendar
15 Mar 21
13 Apr 21
31 Jul 21
Financial summary
Quarter (USD) |
Jan 21 | Oct 20 | Jul 20 | Apr 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Jul 20 | Jul 19 | Jul 18 | Jul 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3M | 3M | 3M | 3M | 3M | 3M |
Cash burn (monthly) | 179.67K | (positive/no burn) | 198K | (positive/no burn) | 69.67K | (positive/no burn) |
Cash used (since last report) | 441.3K | n/a | 486.33K | n/a | 171.11K | n/a |
Cash remaining | 2.56M | n/a | 2.52M | n/a | 2.83M | n/a |
Runway (months of cash) | 14.3 | n/a | 12.7 | n/a | 40.6 | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Dec 20 | Lee Tom Y | Common Stock | Buy | Aquire P | No | No | 0.65 | 851 | 553.15 | 4,696,368 |
22 Dec 20 | Lee Tom Y | Common Stock | Buy | Aquire P | No | No | 0.662 | 45,299 | 29.99K | 4,695,517 |
21 Dec 20 | Lee Tom Y | Common Stock | Buy | Aquire P | No | No | 0.68 | 7,859 | 5.34K | 4,650,218 |
17 Dec 20 | Lee Tom Y | Common Stock | Buy | Aquire P | No | No | 0.65 | 4,712 | 3.06K | 4,642,359 |
16 Dec 20 | Lee Tom Y | Common Stock | Buy | Aquire P | No | No | 0.665 | 20,000 | 13.3K | 4,637,647 |
24 Jun 20 | Lee Tom Y | Common Stock | Other | Dispose J | Yes | No | 0 | 10,732,222 | 0 | 13,401,951 |
22 Jun 20 | Lee Tom Y | Common Stock | Buy | Aquire P | No | No | 1.72 | 13,124 | 22.57K | 4,617,647 |
19 Jun 20 | Lee Tom Y | Common Stock | Buy | Aquire P | No | No | 1.85 | 10,000 | 18.5K | 4,604,523 |
18 Jun 20 | Lee Tom Y | Common Stock | Buy | Aquire P | No | No | 1.7499 | 30,000 | 52.5K | 4,594,523 |
17 Jun 20 | Lee Tom Y | Common Stock | Buy | Aquire P | No | No | 1.605 | 26,876 | 43.14K | 4,564,523 |
Institutional ownership Q2 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
0.0% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 1 |
Opened positions | 1 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares |
Current |
---|---|
Total value | 25K |
Total shares | 13.83K |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners |
Shares | Value |
---|---|---|
Kirr Marbach & Co | 13.83K | $25K |
Financial report summary
?Management Discussion
- Our results of operations have fluctuated significantly from period to period in the past and are likely to continue to do so in the future. We anticipate that our results of operations will be affected for the foreseeable future by several factors that may contribute to these periodic fluctuations, including fluctuations in the buying patterns of our current or potential customers for which we have no visibility, the mix of product sales including a change in the percentage of higher or lower margin formulations and packaging configurations of our products, the cost of product sales including component costs, our inability for any reason to be able to meet demand, the achievement and timing of research and development and regulatory milestones, unforeseen changes in expenses, including non-cash expenses such as the fair value of equity awards granted and the fair value change of derivative liabilities, the calculation of which includes several variable assumptions, and unforeseen manufacturing or supply issues, among other issues. Due to these fluctuations, we believe that the period-to-period comparisons of our operating results are not a reliable indication of our future performance. As of the date of this filing, we are not aware of any trends in these factors or events or conditions that we believe are reasonably likely to impact our results of operations in the future.
Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Good
|
Removed:
decreased
Financial reports
10-Q
2021 Q2
Quarterly report
15 Mar 21
10-Q
2021 Q1
Quarterly report
15 Dec 20
10-K
2020 FY
Annual report
8 Oct 20
10-Q
2020 Q3
Quarterly report
11 Jun 20
10-Q
2020 Q2
Quarterly report
12 Mar 20
10-Q
2020 Q1
Quarterly report
13 Dec 19
10-K
2019 FY
Annual report
29 Oct 19
10-Q
2019 Q3
Quarterly report
13 Jun 19
10-Q
2019 Q2
Quarterly report
6 Mar 19
10-Q
2019 Q1
Quarterly report
13 Dec 18
Current reports
8-K
PURE Bioscience Reports Fiscal 2021 Second Quarter
15 Mar 21
8-K
Submission of Matters to a Vote of Security Holders
27 Jan 21
8-K
PURE Bioscience Reports Fiscal First Quarter 2021
15 Dec 20
8-K
PURE Bioscience Reports Fiscal 2020
8 Oct 20
8-K
PURE Bioscience Reports Fiscal 2020 Third Quarter
11 Jun 20
8-K
PURE Bioscience Announces Exclusive Distribution
21 May 20
8-K
PURE Bioscience Reports Fiscal 2020 Second Quarter
12 Mar 20
8-K
Submission of Matters to a Vote of Security Holders
4 Feb 20
8-K
PURE Bioscience Reports Fiscal 2020 Q1 Financial Results
13 Dec 19
8-K
Changes in Registrant's Certifying Accountant
20 Nov 19
Registration and prospectus
POS AM
Prospectus update (post-effective amendment)
19 Oct 20
424B3
Prospectus supplement
15 Jun 20
424B3
Prospectus supplement
13 Mar 20
424B3
Prospectus supplement
17 Dec 19
POS AM
Prospectus update (post-effective amendment)
31 Oct 19
424B3
Prospectus supplement
14 Jun 19
424B3
Prospectus supplement
7 Mar 19
424B3
Prospectus supplement
14 Dec 18
424B3
Prospectus supplement
13 Nov 18
POS AM
Prospectus update (post-effective amendment)
25 Oct 18
Proxies
DEF 14A
Definitive proxy
8 Dec 20
PRE 14A
Preliminary proxy
20 Nov 20
DEF 14A
Definitive proxy
19 Dec 19
DEF 14A
Definitive proxy
20 Dec 18
DEF 14A
Definitive proxy
7 Dec 17
DEFA14A
Additional proxy soliciting materials
7 Dec 17
DEF 14A
Definitive proxy
7 Dec 16
DEFA14A
Additional proxy soliciting materials
7 Dec 16
DEF 14A
Definitive proxy
22 Dec 15
DEFA14A
Additional proxy soliciting materials
22 Dec 15
Other
EFFECT
Notice of effectiveness
26 Oct 20
EFFECT
Notice of effectiveness
5 Nov 19
EFFECT
Notice of effectiveness
1 Nov 18
EFFECT
Notice of effectiveness
30 Oct 17
EFFECT
Notice of effectiveness
31 Aug 17
EFFECT
Notice of effectiveness
14 Feb 17
EFFECT
Notice of effectiveness
1 Nov 15
EFFECT
Notice of effectiveness
11 Jan 15
CORRESP
Correspondence with SEC
7 Jan 15
CORRESP
Correspondence with SEC
30 Dec 14
Ownership
4
PURE BIOSCIENCE / Tom Y Lee ownership change
28 Dec 20
4
PURE BIOSCIENCE / Tom Y Lee ownership change
26 Jun 20
4
PURE BIOSCIENCE / Tom Y Lee ownership change
22 Jun 20
4
PURE BIOSCIENCE / Thomas Richard Myers ownership change
22 Jun 20
4
PURE BIOSCIENCE / Tom Y Lee ownership change
18 Jun 20
4
PURE BIOSCIENCE / Dale Okuno ownership change
19 May 20
4
PURE BIOSCIENCE / Thomas Richard Myers ownership change
19 May 20
4
PURE BIOSCIENCE / Tom Y Lee ownership change
19 May 20
4
PURE BIOSCIENCE / Mark Stuart Elliott ownership change
19 May 20
4
PURE BIOSCIENCE / Ivan Chen ownership change
19 May 20
Reddit threads
GME Announces Early Redemption of Senior Notes
13 Apr 21
THE LOUNGE: thoughts, noob stuff, low effort, brokers, zero DD, non pennies - April 10, 2021
9 Apr 21
Do not despair +400 $GME apes! 🦍 Coming for you tomorrow 💎🙌🚀
11 Mar 21
Me and the boys watching GME today
11 Mar 21
To combat the negativity: GME is up 441% since 2/24
11 Mar 21
GME Megathread for March 11, 2021
11 Mar 21
Pfizer - PFE laggard or just dead money
8 Mar 21
THE LOUNGE: thoughts, noob stuff, low effort, brokers, zero DD, non pennies - March 08, 2021
7 Mar 21
Stay away from NAGA
4 Mar 21
Warren Buffet's stock strategy is more relevant now than ever.
4 Mar 21